1H and 31P NMR studies indicate reduced bile constituents in patients with biliary obstruction and infection

NMR in Biomedicine

Volumn 22, Issue 2, 2009, Pages 220-228

  Bala, Lakshmi ^a   Tripathi, Pratima ^a   Bhatt, Ganesh ^a   Das, Kshaunish ^a   Roy, Raja ^a   Choudhuri, Gourdas ^a   Khetrapal, C L ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

1H and 31P NMR; Bile; Biochemicals; Body fluid; Cholangitis; Cholestasis; Infection; Obstructive jaundice

Indexed keywords

1H AND 31P NMR; BILE; BIOCHEMICALS; CHOLANGITIS; CHOLESTASIS; INFECTION; OBSTRUCTIVE JAUNDICE;

CHOLESTEROL; NUCLEAR MAGNETIC RESONANCE;

BODY FLUIDS;

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILE ACID; BILIRUBIN; CHOLESTEROL; CHOLINE; LYSOPHOSPHATIDYLCHOLINE; PHOSPHATE; PHOSPHATIDYLCHOLINE; PHOSPHOETHANOLAMINE; BIOLOGICAL MARKER; DIAGNOSTIC AGENT; PHOSPHORUS; PROTON;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE ACID METABOLISM; BILE COMPOSITION; BILE FLOW; BILE LEVEL; BILIARY TRACT INFECTION; BILIRUBIN BLOOD LEVEL; CHOLANGITIS; CHOLESTEROL BILE LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOWN REGULATION; EXTRAHEPATIC BILE DUCT OBSTRUCTION; FEMALE; FEVER; HUMAN; INTERMETHOD COMPARISON; INTRAHEPATIC BILE DUCT; JAUNDICE; LEUKOCYTE COUNT; LIVER CELL; MAJOR CLINICAL STUDY; MALE; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTHROMBIN TIME; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE ANALYSIS; BILE; CHEMISTRY; METABOLISM; METHODOLOGY; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBSTRUCTIVE JAUNDICE; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; BILE; BIOLOGICAL MARKERS; CHOLANGITIS; CHOLESTASIS, EXTRAHEPATIC; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PHOSPHORUS ISOTOPES; PROTONS; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 64549110797     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1308     Document Type: Article

References (49)

1. Sleisenger MH, Fordtran JS. Gastrointestinal Disease, Vol. 2, 5th edn. W.B. Saunders Company: Philadelphia, 1993; 1106-1118.
2. Hay DW, Carey MC. Chemical species of lipids in bile. Hepatology 1990; 12: 6s-14s.
3. Yamada T, Alpers DH, Owyang C, Powell DW, Silverstein FE. Bile secretion. In Text Book of Gastroenterology, Vol. 1, 2nd edn. JB Lippincott Company: Philadelphia, 1995; 383-404.
4. Zollner G, Marschall HU, Wagner M, Trauner M. Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. Mol Pharm. 2006; 3: 231-251.
5. Geier A, Wagner M, Dietrich CG, Trauner M. Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. Biochim Biophys Acta. 2007; 1773: 283-308.
6. Dumonceau JM, Casco C, Landoni N, Frossard JL, Hadengue A, Pache JC, Genevay M, Morel P, Kumar N, Bongiovanni M. A new method of biliary sampling for cytopathological examination during endoscopic retrograde cholangiography. Am J Gastroenterol. 2007; 102: 550-557.
7. Avila-Funes JA, Montano-Loza A, Zepeda-Gomez S, Meza-Junco J, Melano-Carranza E, Valdovinas-Andraca F, Valdovinas-Diaz MA, Ponce de Leon-Rosales S. Endoscopic retrograde cholangiopancreatography in the elderly. Rev Invest Clin. 2005; 57: 666-670.
8. van Delden OM, Lameris JS. Percutaneous drainage and stenting for palliation of malignant bile duct obstruction. Eur Radiol. 2008; 18: 448-456.
9. Qian XJ, Zhai RY, Dai DK, Yu P, Gao L. Treatment of malignant biliary obstruction by combined percutaneous transhepatic biliary drainage with local tumor treatment. World J Gastroenterol. 2006; 12: 331-335.
10. Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J. Hepatol. 2002; 37: 806-813.
11. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet 2005; 366: 1303-1314.
12. Misra S, Chaturvedi A, Misra NC. Gallbladder cancer. Curr Treat Options Gastroenterol. 2006; 9: 95-106.
13. Baijal SS, Dhiman RK, Gupta S, Sharma BC, Roy S, Agarwal DK, Choudhuri G, Saraswat VA, Naik SR. Percutaneous transhepatic biliary drainage in the management of obstructive jaundice. Trop Gastroenterol. 1997; 18: 167-171.
14. Kipp BR, Stadheim LM, Halling SA, Pochron NL, Harmsen S, Nagorney DM, Sebo TJ, Therneau TM, Gores GJ, de Groen PC, Baron TH, Levy MJ, Halling KC, Roberts LR. A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures. Am J Gastroenterol. 2004; 99: 1675-1681.
15. Kumar R, Sharma BC, Singh J, Sarin SK. Endoscopic biliary drainage for severe acute cholangitis in biliary obstruction as a result of malignant and benign diseases. J. Gastroenterol Hepatol. 2004; 19: 994-997.
16. Jain MK, Jain R. Acute bacterial cholangitis. Curr Treat Options Gastroenterol. 2006; 9: 113-121.
17. Lapidus A, Akerlund JE, Einarsson C. Gallbladder bile composition in patients with Crohn's disease. World J Gastroenterol. 2006; 12: 70-74.
18. Pereira SP, Bain IM, Kumar D, Dowling RH. Bile composition in inflammatory bowel disease: ileal disease and colectomy, but not colitis, induce lithogenic bile. Aliment Pharmacol Ther. 2003; 17: 923-933.
19. Combes B, Carithers RL, Maddrey WC, Munoz S, Garcia-Tsao G, Bonner GF, Boyer JL, Luketic VA, Shiffman ML, Peters MG, White H, Zetterman RK, Risser R, Rossi SS, Hofmann AF. Biliary bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology 1999; 29: 1649-1654.
20. Gustafsson U, Sahlin S, Einarsson C. Biliary lipid composition in patients with cholesterol and pigment gallstones and gallstone-free subjects: deoxycholic acid does not contribute to formation of cholesterol gallstones. Eur J Clin Invest. 2000; 30: 1099-1106.
21. Geuken E, Visser D, Kuipers F, Blokzijl H, Leuvenink HG, de Jong KP, Peeters PM, Jansen PL, Slooff MJ, Gouw AS, Porte RJ. Rapid increase of bile salt secretion is associated with bile duct injury after human liver transplantation. J. Hepatol. 2004; 41: 1017-1025.
22. 31P MRS applications. Liver Int 2005; 25: 273-281.
23. Kristiansen TZ, Bunkenborg J, Gronborg M, Molina H, Thuluvath PJ, Argani P, Goggins MG, Maitra A, Pandey A. A proteomic analysis of human bile. Mol Cell Proteomics. 2004; 3: 715-728.
24. Nouri-Sorkhabi MH, Gruca MA, Kuchel PW, Gaskin KJ. Phospholipid changes in children with pancreatic sufficiency and insufficiency. Clin Chim Acta. 1999; 281: 89-100.
25. Bjerve KS, Daae LN, Bremer J. The selective loss of lysophospholipids in some commonly used lipid-extraction procedures. Anal Biochem. 1974; 58: 238-245.
26. Lindon JC, Nicholson JK, Everett JR. NMR spectroscopy of biofluids. Ann Rep NMR Spectrosc. 1999; 38: 1-88.
27. 1H NMR spectroscopic method for diagnosis of malabsorption syndrome: a pilot study. NMR Biomed. 2004; 17: 69-75.
28. 1H NMR spectroscopy. Magn Reson Med. 2006; 56: 738-744.
29. 1H NMR spectroscopy of ascitic fluid: discrimination between malignant and benign ascites and comparison of the results with conventional methods. NMR Biomed. 2008; 21: 606-614.
30. 1H MR spectroscopy. Radiology 2003; 229: 587-592.
31. Cox IJ, Sharif A, Cobbold JF, Thomas HC, Taylor-Robinson SD. Current and future applications of in vitro magnetic resonance spectroscopy in hepatobiliary disease. World J Gastroenterol. 2006; 12: 4773-4783.
32. Fry DE. Obstructive jaundice. Causes and surgical interventions. Postgrad Med. 1988; 84: 217-222.
33. Gomez-Roel X, Arrieta O, Leon-Rodriguez E. Prognostic factors in gallbladder and biliary tract cancer. Med Oncol. 2007; 24: 77-83.
34. Hawkins WG, DeMatteo RP, Jarnagin WR, Ben-Porat L, Blumgart LH, Fong Y. Jaundice predicts advanced disease and early mortality in patients with gallbladder cancer. Ann Surg Oncol. 2004; 11: 310-315.
35. Fuchs M, Sanyal AJ. Sepsis and cholestasis. Clin Liver Dis. 2008; 12: 151-172.
36. Simko V, Kelley RE, Dincsoy HP. Predicting severity of liver disease: twelve laboratory tests evaluated by multiple regression. J. Int Med Res. 1985; 13: 249-254.
37. Mann DV, Lam WW, Magnus Hjelm N, So NM, Yeung DK, Metreweli C, Lau WY. Biliary drainage for obstructive jaundice enhances hepatic energy status in humans: a 31-phosphorus magnetic resonance spectroscopy study. Gut 2002; 50: 118-122.
38. Younes RN, Vydelingum NA, Derooij P, Scognamiglio F, Andrade L, Posner MC, Brennan MF. Metabolic alterations in obstructive jaundice: effect of duration of jaundice and bile-duct decompression. HPB Surg. 1991; 5: 35-48.
39. Nakayama F. Composition of gallstones and bile species differences. J. Lab Clin Med. 1969; 73: 623-630.
40. Xu GR, Kirk CJ, Goode AW. Changes in biliary lipid concentrations in bile duct obstruction: an experimental study. J. R Soc Med. 1986; 79: 522-527.
41. 1H NMR spectroscopy. Lipids 2006; 41: 577-589.
42. Arresse M, Trauner M. Molecular aspects of bile formation and cholestasis. Trends Mol Med. 2003; 9: 558-564.
43. Elferink RO. Cholestasis. Gut 2003; 52(Suppl 2): ii42-ii48.
44. Baren EJ, Peterson LR, Finegold SM. Conventional and rapid microbiological methods for identification of bacteria and fungi. In Bailey and Scott's Diagnostic Microbiology, 9th edn. Mosby-Year Book Inc: St Louis, MO, 1994; 97-122.
45. Padillo FJ, Andicoberry B, Muntane J, Lozano JM, Mino G, Sitges-Serra A, Pera-Madrazo C. Factors predicting nutritional derangements in patients with obstructive jaundice: multivariate analysis. World J Surg 2001; 25: 413-418.
46. Younes RN, Vydelingum NA, Derooij P, Scognamiglio F, Andrade L, Posner MC, Brennan MF. Metabolic alterations in obstructive jaundice: effect of duration of jaundice and bile duct decompression. HPB Surg 1991; 5: 35-48.
47. Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WM, TaylorRobinson SD, Thillainayagam AV, Thomas HC, Thursz MR, Wasan H. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document Gut. 2002; 51 (Suppl. 6): VI1-VI9.
48. 31P magnetic resonance spectroscopy of human liver in elderly patients: changes according to nutritional status and inflammatory state. Metabolism 1996; 45: 1059-1061.
49. Donner MG, Keppler D. Upregulation of basolateral multidrug resistance protein 3 (Mrp3) in cholestatic rat liver. Hepatology 2001; 34: 351-359.